The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s oral biologics & biosimilar drugs market report forecasts the oral biologics & biosimilar drugs market size to grow to $11.77 Billion by 2027, with a CAGR (compound annual growth rate) of more than 18%.

Learn More On The Oral Biologics & Biosimilar Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Oral Biologics & Biosimilar Drugs Market Size Forecast
The global oral biologics & biosimilar drugs market is expected to grow from $4.91 billion in 2022 to $5.94 billion in 2023 at a compound annual growth rate (CAGR) of 21.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral biologics & biosimilar drugs market is expected to grow from $11.77 billion in 2027 at a CAGR of 18.6%.

North America held the largest oral biologics & biosimilar drugs market share, and Middle East was the fastest-growing region in 2022.

Key Oral Biologics & Biosimilar Drugs Market Driver ­– Rise In The Prevalence Of Chronic Diseases
According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market.

Request for A Sample Of The Global Oral Biologics & Biosimilar Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

Key Oral Biologics & Biosimilar Drugs Market Trend – Creating Of New Insulin Biosimilars
The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in August 2020, Biocon Biologics India Ltd., an India-based fully integrated global biosimilars organization, in partnership with Mylan, a US-based biosimilar company, has launched Semglee, insulin glargine injection in the U.S.

Oral Biologics & Biosimilar Drugs Market Segment
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’S Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis, and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, and Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Oral Biologics & Biosimilar Drugs Market Major Players and Strategies
Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca PLC., Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan PLC., Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline PLC., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche.

The Oral Biologics & Biosimilar Drugs Global Market Report 2023 covers regional data on oral biologics & biosimilar drugs market size, oral biologics & biosimilar drugs market trends and drivers, opportunities, strategies, and oral biologics & biosimilar drugs market competitor analysis. The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

A biosimilar refers to a medication that closely resembles a biologic medication in both structure and function. A biologic drug, however, is a treatment created using a biological system, such as yeast, bacteria, or animal cells. A biological product is considered “biosimilar” if it is extremely similar to and bears no discernible clinical differences from an FDA-approved reference product already in use.

View More Reports Related To The Oral Biologics & Biosimilar Drugs Market –
Biologics Global Market Report 2023
Biosimilars Global Market Report 2023
Dental Diagnostic Imaging Devices And Equipment Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: